Home
About US
Who We Are
Mission & Vision
Board
Values
Partners
Products
Pipeline
Career
News
Safety Report
Contact Us
Home
About US
Who We Are
Mission & Vision
Board
Values
Partners
Products
Pipeline
Career
News
Safety Report
Contact Us
Facebook
Linkedin
X Twitter
© Copyright 2026
Safety Report
مستحضرات الشركة الان متوفرة في الشركة المصرية لتجارة الادوية و هيئة الشراء الموحد
Our Concern is Patient Health & Safety
STIO Pharmacovigilance Group Contact Details
STIO QPPV
Mail:
[email protected]
Tel.:
0224500837
Please enable JavaScript in your browser to complete this form.
Please enable JavaScript in your browser to complete this form.
Patient Initials
*
First
Last
Check Paragraph Email
Date of birth
*
Age
*
Gender
*
Male
Female
Country
...Choose...
Afghanistan
Albania
Algeria
Andorra
Angola
Antigua and Barbuda
Argentina
Armenia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo (Congo-Brazzaville)
Congo (Congo-Kinshasa)
Costa Rica
Croatia
Cuba
Cyprus
Czechia (Czech Republic)
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini (Swaziland)
Ethiopia
Fiji
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
North Korea
North Macedonia
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Yemen
Zambia
Zimbabwe
Date of adverse reaction (copy)
*
Check all appropriate to adverse reaction
Involved or prolonged inpatient hospitalization
Involved persistence / significance / disability
Life threatening
Congenital anomaly
Other
Paragraph Text
Suspect drug(s) information
*
...Choose...
Nanajics 4 mcg/ml
Levobupivacaine – SLS 1.25 mg/ml
Xoforik 50 mcg/ml
Doxapram HCL – SLS 2 mg/ml
Ropivacaine – SLS 2 mg/ml
Did reaction diminish after stopping drug?
Yes
No
N/A
Did reaction reappear after re-administration?
*
Yes
No
N/A
Health-care provider
Pharmacist
Physician
Patient
Other
Single Line Text
Single Line Text (copy)
Numbers
Paragraph Text
Date of this report
Report type
*
Initial
Follow up
Your Email
*
Subject
*
Submit
